-
Something wrong with this record ?
Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry
Ján Stariat, Petra Kovaříková, Radim Kučera, Jiří Klimeš, Danuta S. Kalinowski, Des R. Richardson, Raimo A. Ketola
Language English Country Germany
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12403
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
NLK
ProQuest Central
from 2013-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2003-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2013-01-01 to 1 year ago
- MeSH
- Microsomes, Liver metabolism MeSH
- Humans MeSH
- Antineoplastic Agents chemistry metabolism MeSH
- Tandem Mass Spectrometry methods MeSH
- Thiosemicarbazones chemistry metabolism MeSH
- Chromatography, High Pressure Liquid methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) is a promising analogue of the dipyridyl thiosemicarbazone class currently under development as a potential anti-cancer drug. In fact, this class of agents shows markedly greater anti-tumor activity and selectivity than the clinically investigated thiosemicarbazone, Triapine®. However, further development of DpC requires detailed data concerning its metabolism. Therefore, we focused on the identification of principal phase I and II metabolites of DpC in vitro. DpC was incubated with human liver microsomes/S9 fractions and the samples were analyzed using ultra-performance liquid chromatography (UPLC(TM)) with electrospray ionization quadrupole-time-of-flight (Q-TOF) mass spectrometry. An Acquity UPLC BEH C(18) column was implemented with 2 mM ammonium acetate and acetonitrile in gradient mode as the mobile phase. The chemical structures of metabolites were proposed based on the accurate mass measurement of the protonated molecules as well as their main product ions. Ten phase I and two phase II metabolites were detected and structurally described. The metabolism of DpC occurred via oxidation of the thiocarbonyl group, hydroxylation and N-demethylation, as well as the combination of these reactions. Conjugates of DpC and the metabolite, M10, with glucuronic acid were also observed as phase II metabolites. Neither sulfate nor glutathione conjugates were detected. This study provides the first information about the chemical structure of the principal metabolites of DpC, which supports the development of this promising anti-cancer drug and provides vital data for further pharmacokinetic and in vivo metabolism studies.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031807
- 003
- CZ-PrNML
- 005
- 20170411114435.0
- 007
- ta
- 008
- 131002s2013 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00216-012-6562-x $2 doi
- 035 __
- $a (PubMed)23180090
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Stariat, Ján $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
- 245 10
- $a Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry / $c Ján Stariat, Petra Kovaříková, Radim Kučera, Jiří Klimeš, Danuta S. Kalinowski, Des R. Richardson, Raimo A. Ketola
- 520 9_
- $a Di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) is a promising analogue of the dipyridyl thiosemicarbazone class currently under development as a potential anti-cancer drug. In fact, this class of agents shows markedly greater anti-tumor activity and selectivity than the clinically investigated thiosemicarbazone, Triapine®. However, further development of DpC requires detailed data concerning its metabolism. Therefore, we focused on the identification of principal phase I and II metabolites of DpC in vitro. DpC was incubated with human liver microsomes/S9 fractions and the samples were analyzed using ultra-performance liquid chromatography (UPLC(TM)) with electrospray ionization quadrupole-time-of-flight (Q-TOF) mass spectrometry. An Acquity UPLC BEH C(18) column was implemented with 2 mM ammonium acetate and acetonitrile in gradient mode as the mobile phase. The chemical structures of metabolites were proposed based on the accurate mass measurement of the protonated molecules as well as their main product ions. Ten phase I and two phase II metabolites were detected and structurally described. The metabolism of DpC occurred via oxidation of the thiocarbonyl group, hydroxylation and N-demethylation, as well as the combination of these reactions. Conjugates of DpC and the metabolite, M10, with glucuronic acid were also observed as phase II metabolites. Neither sulfate nor glutathione conjugates were detected. This study provides the first information about the chemical structure of the principal metabolites of DpC, which supports the development of this promising anti-cancer drug and provides vital data for further pharmacokinetic and in vivo metabolism studies.
- 650 _2
- $a protinádorové látky $x chemie $x metabolismus $7 D000970
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $x metody $7 D002851
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jaterní mikrozomy $x metabolismus $7 D008862
- 650 _2
- $a tandemová hmotnostní spektrometrie $x metody $7 D053719
- 650 _2
- $a thiosemikarbazony $x chemie $x metabolismus $7 D013882
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kovaříková, Petra $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
- 700 1_
- $a Kučera, Radim $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
- 700 1_
- $a Klimeš, Jiří $u Department of Pharmaceutical Chemistry and Drug Analysis, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
- 700 1_
- $a Kalinowski, Danuta S. $u Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Richardson, Des R. $u Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Ketola, Raimo A. $u Centre for Drug Research, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
- 773 0_
- $w MED00006638 $t Analytical and bioanalytical chemistry $x 1618-2650 $g Roč. 405, č. 5 (2013), s. 1651-1661
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23180090 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20170411114734 $b ABA008
- 999 __
- $a ok $b bmc $g 995894 $s 830252
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 405 $c 5 $d 1651-1661 $i 1618-2650 $m Analytical and bioanalytical chemistry $n Anal Bioanal Chem $x MED00006638
- GRA __
- $a NT12403 $p MZ0
- LZP __
- $a Pubmed-20131002